Valeria Cardinali

Perugia, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Durable remission despite transplantation with active disease in therapy-related NUP98::TOP1-rearranged acute myeloid leukemia.

Durable remission despite transplantation with active disease in therapy-related NUP98::TOP1-rearranged acute myeloid leukemia.

Journal: Annals of hematology
Published: March 10, 2026

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal
Published: December 04, 2025

Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.

Immunomodulatory effect of dasatinib plus blinatumomab versus ponatinib plus blinatumomab in newly diagnosed Ph+ acute lymphoblastic leukemia.

Journal: Leukemia
Published: August 26, 2025

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal
Published: July 29, 2025

Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports.

Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports.

Journal: Annals of hematology
Published: May 11, 2025

Safe administration of venetoclax-obinutuzumab in a chronic lymphocytic leukemia patient with Brugada syndrome.

Safe administration of venetoclax-obinutuzumab in a chronic lymphocytic leukemia patient with Brugada syndrome.

Journal: Annals of hematology
Published: February 19, 2025

Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study.

Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study.

Journal: Haematologica
Published: July 24, 2024

Prescription patterns of venetoclax in acute myeloid leukemia.

Prescription patterns of venetoclax in acute myeloid leukemia.

Journal: Hematological oncology
Published: July 11, 2024

The Leukemic Isocitrate Dehydrogenase (IDH) 1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs).

The Leukemic Isocitrate Dehydrogenase (IDH) 1/2 Mutations Impair Myeloid and Erythroid Cell Differentiation of Primary Human Hematopoietic Stem and Progenitor Cells (HSPCs).

Journal: Cancers
Published: June 23, 2024

Starry sky pattern predicts RAS pathway activation in NPM1-mutated acute myeloid leukemia.

Starry sky pattern predicts RAS pathway activation in NPM1-mutated acute myeloid leukemia.

Journal: American journal of hematology
Published: April 11, 2024

Ponatinib alone or with chemo-immunotherapy in heavily pre treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life study.

Ponatinib alone or with chemo-immunotherapy in heavily pre treated Philadelphia-like acute lymphoblastic leukemia: a CAMPUS ALL real-life study.

Journal: Haematologica
Published: March 05, 2024

Correction to: One disease, two faces: clonally-related AML and MPDCP with skin involvement.

Correction to: One disease, two faces: clonally-related AML and MPDCP with skin involvement.

Journal: Annals of hematology
Published: December 27, 2023
Showing 1-12 of 27

Last Updated: 09/26/2026